Chad M Kormos
Overview
Explore the profile of Chad M Kormos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
71
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lewin A, Hayes J, Zhong D, Zhang D, Kormos C, Mascarella S, et al.
ACS Omega
. 2023 Aug;
8(31):28185-28195.
PMID: 37576635
During the synthesis of deuterated 18-hydroxycortisol, two of the synthetic intermediates have been found to exist in tautomeric forms as the acyclic 18-hydroxy 20-ketone and the cyclic 18,20-hemiketal corresponding to...
2.
Decker A, Rahman M, Kormos C, Hesk D, Darcq E, Kieffer B, et al.
Bioorg Med Chem Lett
. 2023 Jan;
80:129120.
PMID: 36587872
GPR88 is an orphan G protein-coupled receptor which has been implicated in a number of striatal-associated disorders. Herein we describe the synthesis and pharmacological characterization of the first GPR88 radioligand,...
3.
Decker A, Brackeen M, Mohammadkhani A, Kormos C, Hesk D, Borgland S, et al.
ACS Chem Neurosci
. 2022 Mar;
13(7):1082-1095.
PMID: 35325532
Human trace amine-associated receptor subtype 1 (hTAAR1) is a G protein-coupled receptor that has therapeutic potential for multiple diseases, including schizophrenia, drug addiction, and Parkinson's disease (PD). Although several potent...
4.
McClenahan S, Kormos C, Gunnell M, Hambuchen M, Lamb P, Carroll F, et al.
Vaccine
. 2019 Oct;
38(2):336-344.
PMID: 31629568
α-PVP (α-pyrrolidinovalerophenone) and MDPV (3,4-methylenedioxypyrovalerone) are potent abused stimulants that are members of the synthetic cathinone class of drugs. Although these drugs are taken with recreational intent, high doses can...
5.
Ondachi P, Kormos C, Runyon S, Thomas J, Mascarella S, Decker A, et al.
J Med Chem
. 2018 Aug;
61(17):7525-7545.
PMID: 30117738
Past studies have shown that it has been difficult to discover and develop potent and selective κ opioid receptor antagonists, particularly compounds having potential for clinical development. In this study,...
6.
Kormos C, Ondachi P, Runyon S, Thomas J, Mascarella S, Decker A, et al.
J Med Chem
. 2018 Jul;
61(17):7546-7559.
PMID: 30032602
Animal pharmacological studies suggest that potent and selective κ opioid receptor antagonists have potential as pharmacotherapies targeting depression, anxiety, and substance abuse (opiates, alcohol, nicotine, cocaine). We recently reported lead...
7.
Kormos C, Ondachi P, Runyon S, Thomas J, Mascarella S, Decker A, et al.
ACS Med Chem Lett
. 2017 Jul;
8(7):742-745.
PMID: 28740609
Potent and selective κ opioid receptor antagonists have been derived from the -substituted -3,4-dimethyl-4-(3-hydroxyphenyl)piperidine class of pure opioid receptor antagonists. In order to determine if the 3-hydroxyphenyl and/or the piperidine...
8.
Runyon S, Kormos C, Gichinga M, Mascarella S, Navarro H, Deschamps J, et al.
J Org Chem
. 2016 Jul;
81(21):10383-10391.
PMID: 27462910
In order to gain additional information concerning the active conformation of the N-substituted trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine (1) class of opioid receptor antagonists, procedures were developed for the synthesis of structurally rigid N-substituted-6-(3-hydroxyphenyl)3-azabicyclo[3.1.0]hexane...
9.
Kormos C, Gichinga M, Runyon S, Thomas J, Mascarella S, Decker A, et al.
Bioorg Med Chem
. 2016 Jul;
24(16):3842-8.
PMID: 27364611
The potent and selective KOR antagonist JDTic was derived from the N-substituted trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine class of pure opioid antagonists. In previous studies we reported that compounds that did not have a...
10.
Carroll F, Gichinga M, Kormos C, Maitra R, Runyon S, Thomas J, et al.
Bioorg Med Chem
. 2015 Sep;
23(19):6379-88.
PMID: 26342544
The design and discovery of JDTic as a potent and selective kappa opioid receptor antagonist used the N-substituted trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine pharmacophore as the lead structure. In order to determine if the...